Fate Therapeutics Inc
Statements
Cash Flow
Fate Therapeutics Inc (FATE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -23 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.5 | -7.6 | -7.5 | -8.9 | -9.9 | -11 | -13 | -12 | -3.6 | -11 | -17 | -20 | -20 | -26 | -27 | 39 | -31 | -21 | -27 | -32 | -33 | -70 | -65 | -53 | -55 | -75 | -29 | -28 | -38 | -37 | -33 | -32 | -29 | -28 | -34 | -25 | -24 | -23 | -31 | -23 | -102 | |
| 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.9 | 1.0 | 1.2 | 1.5 | 2.2 | 2.8 | 3.0 | 3.2 | 4.8 | 4.2 | 4.5 | 4.7 | 4.9 | 4.8 | 4.7 | 4.6 | 4.8 | 3.3 | 3.3 | 3.2 | 3.1 | 2.1 | 2.8 | 11 | |
| 0.8 | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 | 1.4 | 1.5 | 1.6 | 1.8 | 3.9 | 4.4 | 4.6 | 4.6 | 6.9 | 7.2 | 7.8 | 8.8 | 13 | 13 | 14 | 15 | 19 | 21 | 19 | 19 | 11 | 13 | 10 | 9.5 | 11 | 9.6 | 12 | 9.1 | 7.4 | 7.2 | 4.9 | 5.5 | 3.9 | 3.5 | 18 | |
| 0.9 | 0.9 | 1.2 | 1.3 | 1.3 | 1.3 | 1.5 | 1.6 | 1.8 | 1.9 | 3.9 | 4.5 | 4.7 | 4.3 | 6.9 | 7.2 | 7.8 | 8.8 | 13 | 21 | 14 | 7.7 | 19 | 21 | 19 | 7.5 | 11 | 5.8 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.6 | -0.2 | 1.8 | -0.2 | -0.2 | 0.7 | 0.3 | 2.1 | 0.5 | -1.1 | -0.1 | 0.9 | 4.0 | -1.2 | -0.7 | -5.1 | -6.4 | -0.6 | 6.1 | -0.5 | 9.3 | -13 | -11 | -1.2 | 10 | -33 | 12 | 10 | -2.8 | -0.2 | 0.6 | -3.8 | 3.1 | -1.9 | -5.4 | 0.1 | 0.5 | 1.1 | -6.0 | -0.1 | -4.5 | |
| 0.0 | 0.0 | 0.2 | 0.4 | 0.4 | 0.8 | 0.2 | 0.3 | 0.7 | 1.1 | 1.7 | 1.8 | 1.3 | 2.6 | 1.1 | 0.6 | 1.0 | 2.3 | 4.0 | 14 | 15 | 18 | 10 | 10 | 8.7 | 6.7 | 3.2 | 2.2 | 0.6 | 0.2 | 0.1 | 0.1 | 0.5 | 0.1 | 1.2 | 1.4 | 2.2 | 1.2 | 0.2 | 0.1 | 3.7 | |
| 0.5 | 6.0 | -38 | 1.3 | 14 | 13 | -44 | 14 | 13 | 16 | 8.8 | -92 | 36 | -111 | 24 | 35 | -54 | -166 | -472 | -1.4 | 78 | 71 | -7.0 | 40 | 80 | 53 | 9.3 | 33 | 25 | 45 | 17 | -53 | 25 | 23 | 43 | 20 | 21 | 28 | 24 | 15 | 87 | |
| 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 10 | 0.0 | 0.0 | 0.0 | – | – | – | – | 2.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 10 | 0.2 | -0.2 | 0.0 | 0.1 | 0.2 | -0.3 | 0.0 | 136 | 3.0 | 1.3 | 0.7 | 163 | 2.5 | 1.0 | 242 | 0.9 | 4.9 | 5.6 | 415 | -13 | 3.4 | 2.8 | 3.4 | 1.5 | – | 0.2 | – | – | -0.2 | – | -0.7 | 0.7 | -0.7 | – | – | – | – | – | – | – | |
| -1.9 | -2.0 | -2.0 | -2.0 | 8.3 | 4.2 | – | – | – | -1.0 | -1.0 | -1.0 | -1.0 | -14 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 8.3 | 53 | -2.2 | -2.0 | 8.4 | 43 | 0.4 | 1.2 | 137 | 1.9 | 1.3 | 0.7 | 162 | -14 | 1.5 | 276 | 0.9 | 4.9 | 438 | 3.7 | 7.9 | 3.4 | 2.8 | 3.4 | 1.5 | 1.5 | 0.2 | 0.1 | 0.0 | -0.2 | 95 | 1.3 | 0.0 | 3.1 | 0.0 | 1.3 | 2.5 | 1.7 | – | 1.7 | – | |
| 1.2 | 52 | -48 | -9.4 | 12 | 46 | -56 | 3.4 | 147 | 7.3 | -7.5 | -112 | 178 | -150 | -16 | 350 | -84 | -182 | -61 | -30 | 53 | 4.4 | -69 | -9.5 | 27 | -21 | -19 | 4.8 | -13 | 8.5 | 79 | -84 | 1.0 | -1.9 | 8.9 | -3.7 | -0.6 | 6.0 | -7.2 | -7.1 | -9.0 | |
| -7.5 | -7.6 | -7.6 | -9.3 | -10 | -12 | -13 | -12 | -4.3 | -12 | -19 | -22 | -21 | -28 | -28 | 38 | -32 | -23 | -31 | -46 | -48 | -89 | -75 | -63 | -64 | -82 | -32 | -31 | -39 | -37 | -33 | -32 | -30 | -28 | -35 | -26 | -27 | -25 | -31 | -24 | -106 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.